Skip to content
value.today

Thrombolex, Inc.

🇺🇸 Kingston, New Jersey, USAHealth CareFounded 2016
Total raised
$46 M
5 rounds on record
Latest round
$33 M
Feb 2026
First round on record
Nov 2021
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Thrombolex, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2026$33 MNo. 5$10 to $50 million

Thrombolex, Inc.: Raise no. 5, Feb 2026

Investors in this round

22 investors had bought by the notice of Mar 12, 2026: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$33 M of $51 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Includes Conversion of Outstanding Notes
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John J. Cerminaro · Executive Officer
  • Marvin J. Woodall · Executive Officer, Director
  • Michael J. Cerminaro · Executive Officer, Director
  • Clay A. DeMarcus · Director
  • David A. Bonita · Director
  • Keegan A. Harper · Director
  • Paul A. Stewart · Director
  • Sam A. Liang · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Cerminaro, Cfo. Source: SEC Form D, newest notice filed Mar 12, 2026. Read the notice at the SEC.

equitySEC
Jun 2024$1 MNo. 4Under $2 million

Thrombolex, Inc.: Raise no. 4, Jun 2024

Investors in this round

5 investors had bought by the notice of Jun 21, 2024: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $5 M offered; $4 M still to sell
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John A. Cerminaro · Executive Officer
  • Michael J. Cerminaro · Executive Officer, Director
  • Tony J. Litwiller · Executive Officer
  • Kelly A. Elliott · Director
  • Marvin J. Woodall · Director
  • Paul A. Stewart · Director
  • Todd A. Richmond · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering amount may be increased by the Issuer”

Signed by John Cerminaro, Cfo. Source: SEC Form D, newest notice filed Jun 21, 2024. Read the notice at the SEC.

debt, optionsSEC
Jun 2023$5 MNo. 3$2 to $10 million

Thrombolex, Inc.: Raise no. 3, Jun 2023

Investors in this round

56 investors had bought by the notice of May 28, 2024: 56 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John A. Cerminaro · Executive Officer
  • Michael J. Cerminaro · Executive Officer, Director
  • Tony J. Litwiller · Executive Officer
  • Kelly A. Elliott · Director
  • Marvin J. Woodall · Director
  • Paul A. Stewart · Director
  • Todd A. Richmond · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Cerminaro, Cfo. Source: SEC Form D, newest notice filed May 28, 2024. Read the notice at the SEC.

equitySEC
Jul 2022$2 MNo. 2$2 to $10 million

Thrombolex, Inc.: Raise no. 2, Jul 2022

Investors in this round

50 investors had bought by the notice of Aug 30, 2022: 50 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian G. Firth · Executive Officer, Director
  • John A. Cerminaro · Executive Officer
  • Marvin J. Woodall · Executive Officer, Director
  • Michael J. Cerminaro · Executive Officer, Director
  • Paul A. Stewart · Director
  • Todd A. Richmond · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Cerminaro, Cfo. Source: SEC Form D, newest notice filed Aug 30, 2022. Read the notice at the SEC.

equitySEC
Nov 2021$5 MNo. 1$2 to $10 million

Thrombolex, Inc.: Raise no. 1, Nov 2021

Investors in this round

46 investors had bought by the notice of Nov 29, 2021: 46 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian G. Firth · Executive Officer, Director
  • John A. Cerminaro · Executive Officer
  • Marvin J. Woodall · Executive Officer, Director
  • Michael J. Cerminaro · Executive Officer, Director
  • Paul A. Stewart · Director
  • Todd A. Richmond · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Cerminaro, Cfo. Source: SEC Form D, newest notice filed Nov 29, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Thrombolex, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2026).

    SEC Form D · Mar 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Mar 2026

That is all the official record says: Thrombolex, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Thrombolex, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 56 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Thrombolex, Inc.
NameRoleNamed in
John J. CerminaroExecutive officerMar 2026
Marvin J. WoodallExecutive officerMar 2026
Michael J. CerminaroExecutive officerMar 2026
John A. CerminaroExecutive officerJun 2024
Tony J. LitwillerExecutive officerJun 2024
Brian G. FirthExecutive officerAug 2022
Clay A. DeMarcusDirectorMar 2026
David A. BonitaDirectorMar 2026
Keegan A. HarperDirectorMar 2026
Marvin J. WoodallDirectorMar 2026
Michael J. CerminaroDirectorMar 2026
Paul A. StewartDirectorMar 2026
Sam A. LiangDirectorMar 2026
Kelly A. ElliottDirectorJun 2024
Todd A. RichmondDirectorJun 2024
Brian G. FirthDirectorAug 2022